研究单位：[1]Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China, 510630[2]Peking University[3]Huazhong University of Science and Technology[4]Nanchang University[5]Huizhou Municipal Central Hospital[6]First People's Hospital, Shunde China[7]Shenzhen Third People's Hospital[8]First People's Hospital of Foshan[9]Tang-Du Hospital[10]First Affiliated Hospital of Kunming Medical University[11]Yuebei People's Hospital
HBeAg-negative chronic hepatitis B (CHB) patients with low Level HBsAg and with a history of drug resistance or suboptimal/partial virological response were enrolled. After giving informed consent, patients were treated with nucleoside analog(s) (NAs) once a day and weekly subcutaneous injections of alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 12 weeks. 12 weeks later, NAs was stopped, patients were treated with weekly subcutaneous injections of alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. Treatment endpoint was HBsAg loss(<0.05 IU/mL).
